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Management

Kounis syndrome, also known as allergic vasospastic angina, is a type of acute
coronary syndrome caused by an allergic reaction or immune response to a
substance.[1] It is essentially an “allergic angina” which is believed to be caused
by mast cell activation and release of cytokines and histamine causing spasm of
the artery leading to acute coronary syndrome and acute myocardial infarction.
Stress cardiomyopathy (Takotsubo syndrome), which predominantly affects postmenopausal women, may also occur in anaphylaxis where transient ventricular
dysfunction associated with regional ventricular wall abnormalities extending
beyond the regions of coronary blood supply ensues.[2] The suspected
prevalence of Kounis syndrome in the United states is 1.1% among those that
were hospitalized for allergic, anaphylactic or hypersensitivity reactions [3]. Due
to differences in management strategy, it is important to differentiate between
Kounis syndrome and ACS due to other causes, especially in those with a history
of coronary artery disease.

Results from the cardiac catheterization showed a normal left main artery. The
LAD was 100 percent occluded in the mid segment due to a thrombosed stent in
the LAD and diagonal branch. Left circumflex was a moderate sized nondominant vessel with a stent to the second obtuse marginal branch. There was an
apparent filling defect inside the stent consistent with stent thrombosis. (Figure 2.)
The bypass to the obtuse marginal branch appeared to be occluded without
competitive flow in the distal obtuse marginal branch. The right coronary artery
appeared to be a moderate sized dominant vessel with a 67 percent stenosis in
the mid segment. Saphenous vein graft to the RCA and obtuse marginal branch
were occluded. LIMA to the LAD was widely patent perfusing the LAD without
providing collaterals to the distal RCA. The culprit lesion of the MI was the left
circumflex with visualized filling defect inside the stent consistent with very late
stent thrombosis. The left circumflex artery was stented with a DES and
apposition confirmed by IVUS. (Figure 3.) After catheterization the patient
remained chest pain free and was able to be discharged home after 24 hours of
monitoring.

Management of Kounis syndrome requires understanding of the pathophysiologic
mechanisms behind the disease process. The management strategies for the
ACS and anaphylaxis components of Kounis syndrome may be at odds and
management guidelines are lacking.[7] Strategies for managing each of these
entities should take in to consideration the pathophysiology of the other.

Case
Our patient is a 69-year-old woman with a past medical history of squamous cell
carcinoma of the lung, coronary artery disease status post prior PCI and CABG
(LIMA to LAD, SVG to OM, SVG to PDA), diabetes mellitus type 2, hypertension
and hyperlipidemia who presented for neck pain of one week duration. She said
the neck pain started spontaneously and it was worse with movement of her left
arm and neck, but better with staying still. She also reported intermittent
shortness of breath. Given the history of squamous cell carcinoma and shortness
of breath, a chest CTA and cervical spine CT were performed to rule out PE.
Shortly after receiving the contrast she became flushed, erythematous,
diaphoretic and short of breath. Audible stridor was heard on lung exam. She was
given diphenhydramine, methylprednisolone, famotidine and epinephrine. Her
symptoms improved. She began experiencing retrosternal chest pain that felt
similar to her previous heart attacks. An EKG was obtained which showed ST
elevation in V5-6, II, III and aVF, with ST depressions in V1-4. (Figure 1.) STEMI
alert was called and she was taken to the catheterization lab.

Discussion
Kounis syndrome is recognized as three variants. Type I occurs in patients
without underlying coronary artery disease who have an allergic reaction to a
substance causing acute coronary syndrome due to a coronary spasm. Type II
occurs in patient with underlying asymptomatic coronary artery disease in which
an allergic reaction leads to an arterial spasm and/or plaque rupture. Type III
occurs in the setting of coronary thrombosis, including acute stent thrombosis. In
our patient, the timing of new onset of chest pain and the cardiac cath findings
are consistent with Type II Kounis syndrome.
Shimokawa demonstrated angiographically that coronary artery spasms could be
provoked by giving intracoronary or intravenous injections of in miniature swine
models.[4] Multiple studies using autopsies of patient that suffered cardiac death
from vasospasms have shown vessels with increased mast cells and vasoactive
substances, such as histamine, prostaglandin D2, and leukotrienes. These
substances were seen more in the adventitia when compared with patients with
coronary artery disease.[5]

Typical treatment strategies for anaphylaxis include epinephrine, H1 and H2
blockers, steroids and fluid boluses. Epinephrine can exacerbate myocardial
ischemia or induce arrhythmias. Hypotension should be avoided so medications
like diphenhydramine should be given slowly instead of bolus when possible.
Steroids have side effects in the setting of ACS like coronary wall thinning and
aneurysm formation; however, these medications are life-saving in anaphylaxis
and are appropriately used in the case of Kounis syndrome. Fluid resuscitation
should take into account the patient’s EF or presence of acute pulmonary edema.
Management of ACS should be guideline directed. PCI is the preferred
intervention but fibrinolytics can be used when PCI is not available. Antiplatelet
therapies with aspirin and P2Y12 receptor inhibitors should be given as early as
possible. For patients with a history of aspirin induced allergic reaction this
medication should be withheld and replaced with another antiplatelet medication.
The use of nitroglycerin in Kounis syndrome is considered safe despite the
possibility of allergies existing. Beta-blockers are contraindicated in Kounis
syndrome due to antagonistic effect these medications have on epinephrine, as
well as the precipitation of unopposed alpha-adrenergic stimulation leading to
further vasoconstriction.
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In another study, twelve patients with non-exertional chest pain and nonobstructive fixed coronary disease (less than 50 percent luminal diameter
narrowing) were given histamine to investigate the potential role of coronary
artery H1 receptor agonism in producing coronary artery spasm (CAS).[6]
Histamine at intravenous dose of 0.5 to 1.0 microgram/kg/min provoked CAS in
four patients. These patients were considered by chronic follow-up evaluation to
have non-cardiac etiology for their chest pain syndrome. These observations
indicate that histamine should be included among the specific agents capable of
inducing CAS and provide new insight concerning the mechanisms causing
variant angina pectoris.
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